Key Components and Trends of CVRs in Life Sciences Public M&A Deals

In recent months, the life sciences industry has seen the reemergence of contingent value rights, or CVRs, in public company acquisitions as a way to bridge a valuation gap between buyers and sellers. Recent public deals with CVRs include AstraZeneca’s acquisition of CinCor Pharma completed…

Source: corpgov.law.harvard.edu – Read more